287 related articles for article (PubMed ID: 31722032)
1. Sofosbuvir-/Daclatasvir-based therapy for chronic HCV and HCV/hepatitis B virus coinfected patients in Egypt.
Nagaty A; Helmy SH; Abd El-Wahab EW
Trans R Soc Trop Med Hyg; 2020 Feb; 114(3):200-212. PubMed ID: 31722032
[TBL] [Abstract][Full Text] [Related]
2. Direct-acting antiviral agents in the treatment of chronic hepatitis C-Real-life experience from clinical practices in Pakistan.
Mushtaq S; Mansoor A; Umar M; Khan A; Siddiqi S; Manzoor S
J Med Virol; 2020 Dec; 92(12):3475-3487. PubMed ID: 32129507
[TBL] [Abstract][Full Text] [Related]
3. Sustained virologic response and changes in liver fibrosis parameters following 12-wk administration of generic sofosbuvir and daclatasvir in HIV/HCV-coinfected patients with HCV genotype 4 infection.
Cordie A; Elsharkawy A; Abdel Alem S; Meshaal S; El Akel W; Abdellatif Z; Kamal W; Al Askalany M; Kamel S; Abdel Aziz H; Kandeel A; Esmat G
Trans R Soc Trop Med Hyg; 2020 Apr; 114(4):232-240. PubMed ID: 31925434
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis C virus infected patients. Results in real clinical practice.
Margusino-Framiñán L; Cid-Silva P; Mena-de-Cea A; Rodríguez-Osorio I; Pernas-Souto B; Delgado-Blanco M; Pertega-Díaz S; Martín-Herranz I; Castro-Iglesias A
Rev Esp Quimioter; 2019 Apr; 32(2):137-144. PubMed ID: 30761823
[TBL] [Abstract][Full Text] [Related]
5. Association between interleukin 28B polymorphism and sustained virological response to sofosbuvir plus daclatasvir in chronic hepatitis C genotype 4 Egyptian patients.
Hassanien KS; El-Sayed EM; Ismail RS; Zakarya ZM; Helal GK
J Clin Pharm Ther; 2021 Aug; 46(4):942-949. PubMed ID: 33768560
[TBL] [Abstract][Full Text] [Related]
6. M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals.
Saleh SA; Salama MM; Alhusseini MM; Mohamed GA
World J Gastroenterol; 2020 Jun; 26(21):2864-2876. PubMed ID: 32550761
[TBL] [Abstract][Full Text] [Related]
7. Treatment of hepatitis C virus infection with direct-acting antivirals plus ribavirin eliminates viral RNA from peripheral blood mononuclear cells and reduces virologic relapse in diverse hepatic parenchymal changes.
Abd Alla MDA; Dawood RM; Rashed HAE; Farrag G; Ammar IAE; Mahmoud MMA; Salum GM; Altanbouly AMA; El Meguid MA; Awady MKE
Arch Virol; 2021 Apr; 166(4):1071-1081. PubMed ID: 33533976
[TBL] [Abstract][Full Text] [Related]
8. Daclatasvir and Sofosbuvir Versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect Comparison.
Swallow E; Song J; Yuan Y; Kalsekar A; Kelley C; Peeples M; Mu F; Ackerman P; Signorovitch J
Clin Ther; 2016 Feb; 38(2):404-12. PubMed ID: 26839044
[TBL] [Abstract][Full Text] [Related]
9. Diabetic patients with chronic hepatitis C virus response compared to non diabetics when treated with directly acting antiviral therapy.
Marzaban RN; AlMekhzangy HI; ElAkel W; ElBaz TM; ElShazly YM; ElSaeed K; Anees M; Said M; ElSerafy MA; Esmat GG; Doss WH
Arab J Gastroenterol; 2024 May; 25(2):118-124. PubMed ID: 38378359
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotype 6 in Southwest China: Real-world experience of a retrospective study.
Wu DB; Jiang W; Wang YH; Chen B; Wang ML; Tao YC; Chen EQ; Tang H
J Viral Hepat; 2019 Mar; 26(3):316-322. PubMed ID: 30380166
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Chronic Hepatitis C Infection with Direct Acting Antivirals in Adolescents with Thalassemia Major.
Nagral A; Jhaveri A; Sawant S; Parikh NS; Nagral N; Merchant R; Gandhi M
Indian J Pediatr; 2019 Feb; 86(2):148-153. PubMed ID: 30097845
[TBL] [Abstract][Full Text] [Related]
12. Sofosbuvir-Containing Regimens for Chronic Hepatitis C Are Successful in the Safety-Net Population: A Real-World Experience.
Beck KR; Kim N; Khalili M
Dig Dis Sci; 2016 Dec; 61(12):3602-3608. PubMed ID: 27743164
[TBL] [Abstract][Full Text] [Related]
13. Detection of Occult Hepatitis C Virus Infection in Egyptian Patients Who Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents.
Mashaal AR; Abd El-Hameed M; El Ray AA; Mahmoud Diab T; Dawood RM; Shemis MA; Seyam M
Asian Pac J Cancer Prev; 2022 Sep; 23(9):2965-2971. PubMed ID: 36172658
[TBL] [Abstract][Full Text] [Related]
14. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3.
Belperio PS; Shahoumian TA; Loomis TP; Mole LA; Backus LI
J Hepatol; 2019 Jan; 70(1):15-23. PubMed ID: 30266283
[TBL] [Abstract][Full Text] [Related]
15. A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients.
Duerr M; Schrezenmeier EV; Lehner LJ; Bergfeld L; Glander P; Marticorena Garcia SR; Althoff CE; Sack I; Brakemeier S; Eckardt KU; Budde K; Halleck F
BMC Nephrol; 2019 Feb; 20(1):36. PubMed ID: 30717681
[TBL] [Abstract][Full Text] [Related]
16. Direct Relationship between Interleukin-10 Gene Polymorphism and Hepatocellular Carcinoma Complicated by Direct Acting Antiviral Treatment of Hepatitis C Virus.
Ghanm SE; Shebl NA; El Sayed IET; Abdel-Bary HM; Saad BF; Othman Saad W
Asian Pac J Cancer Prev; 2021 Oct; 22(10):3203-3210. PubMed ID: 34710996
[TBL] [Abstract][Full Text] [Related]
17. High sustained viral response rate in patients with hepatitis C using generic sofosbuvir and daclatasvir in Phnom Penh, Cambodia.
Zhang M; O'Keefe D; Iwamoto M; Sann K; Kien A; Hang V; Brucker C; Jolivet P; Ly S; Chhit D; Balkan S; Marquardt T; Le Paih M; Dousset JP
J Viral Hepat; 2020 Sep; 27(9):886-895. PubMed ID: 32358826
[TBL] [Abstract][Full Text] [Related]
18. Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: Results from the multicenter German hepatitis C cohort (GECCO-03).
Wehmeyer MH; Ingiliz P; Christensen S; Hueppe D; Lutz T; Simon KG; Schewe K; Boesecke C; Baumgarten A; Busch H; Rockstroh J; Schmutz G; Kimhofer T; Berger F; Mauss S; Schulze Zur Wiesch J
J Med Virol; 2018 Feb; 90(2):304-312. PubMed ID: 28710853
[TBL] [Abstract][Full Text] [Related]
19. Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study.
Charatcharoenwitthaya P; Wongpaitoon V; Komolmit P; Sukeepaisarnjaroen W; Tangkijvanich P; Piratvisuth T; Sanpajit T; Sutthivana C; Bunchorntavakul C; Sobhonslidsuk A; Chonprasertsuk S; Siripipattanamongkol C; Sethasine S; Tanwandee T;
BMC Gastroenterol; 2020 Mar; 20(1):47. PubMed ID: 32138687
[TBL] [Abstract][Full Text] [Related]
20. Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV-HCV coinfection and advanced liver disease.
Rockstroh JK; Ingiliz P; Petersen J; Peck-Radosavljevic M; Welzel TM; Van der Valk M; Zhao Y; Jimenez-Exposito MJ; Zeuzem S
Antivir Ther; 2017; 22(3):225-236. PubMed ID: 27845298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
